GDOC hits a 52-week high as aging demographics, tech advances and strength from top holding LLY fuel momentum.
Biotech investing may not be the most obvious place for investors to look right now, but factors may be turning in the category's favor. Multiple rate cuts in the back half of 2025 and a friendlier regulatory regime may position biotech investing as a shrewd option to end the year.
Is now the time to consider biotech ETFs? The stars may be aligning for investing in biotech as 2025 draws to a closer, with ETFs a key route into the space.